Markets
MA Stock Indexes
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
InterMune, Inc. (NQ: ITMN)
9.830 USD  +0.120 (+1.24%)
Official Closing Price  /  Updated: 4:00 PM EDT, Jun 17, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about InterMune, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9 Next >
InterMune Announces Publication of Pricing and Reimbursement Conditions for Esbriet® (pirfenidone) in Italy
June 14, 2013
-- First approved therapy for IPF patients in Italy will be reimbursed from June 29 -- Read More
from PR Newswire
Critical Alerts For Pfizer, CBS, International Paper, Youku.com, and InterMune Released By InvestorsObserver
May 14, 2013
from PR Newswire
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
April 24, 2013
from PR Newswire
InterMune To Release First Quarter Financial Results On April 24
April 17, 2013
from PR Newswire
Morning Research on Gilead Sciences, Halozyme Therapeutics, InterMune, and Seattle Genetics
March 25, 2013
from PR Newswire
Top-Gaining Healthcare Stocks: Rockwell Medical (NASDAQ:RMTI), InterMune (NASDAQ:ITMN), AstraZeneca (NYSE:AZN)
March 22, 2013
from SBWire Direct - Latest Press Releases
FDA's New "Breakthrough" Designation Allows New Drugs to Gain Approval After Just 1 Round of Testing
March 21, 2013
Five Star Equities Provides Stock Research on InterMune and Questcor Pharmaceuticals Read More
from Marketwired News Releases
Esbriet® (pirfenidone) Receives Positive Final Appraisal Determination from NICE for Idiopathic Pulmonary Fibrosis (IPF)
March 20, 2013
-- Also Announces Reimbursement of Esbriet in Finland -- Read More
from PR Newswire
U.S. Food and Drug Administration Approved 30% More Drugs in 2012
February 22, 2013
RDInvesting Provides Stocks Research on InterMune and Repros Therapeutics Read More
from Marketwired News Releases
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
February 21, 2013
from PR Newswire
Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business Officer
February 14, 2013
from PR Newswire
InterMune To Release Fourth Quarter Financial Results On February 21
February 11, 2013
from PR Newswire
NASDAQ Stocks in the News: (NASDAQ: SNDK), (NASDAQ: ITMN)
January 24, 2013
from SBWire Direct - Latest Press Releases
Merger and Acquisition Activity Expected to Rise in 2013 as Big Pharma Companies Flush With Cash
January 21, 2013
Five Star Equities Provides Stock Research on ImmunoGen and InterMune Read More
from Marketwired News Releases
NYSE Earnings Report Database: Genworth Financial, InterMune, Pfizer, General Electric, EMC, and Abbott
January 17, 2013
from PR Newswire
InterMune Announces Pricing of Concurrent Public Offerings of $105,000,000 Principal Amount of Convertible Senior Notes and 13,500,000 Shares of Common Stock
January 16, 2013
from PR Newswire
InterMune Announces Proposed Concurrent Public Offerings Of Common Stock And Convertible Debt
January 14, 2013
from PR Newswire
InterMune Reports Preliminary Fourth Quarter 2012 Esbriet® (pirfenidone) Revenue And Other Recent Business Highlights
January 03, 2013
- Reports Full Enrollment of Phase 3 ASCEND Trial - Read More
from PR Newswire
InterMune To Present At J. P. Morgan Healthcare Conference
January 02, 2013
from PR Newswire
Biotech Industry Experiencing More FDA New Drug Approvals in 2012
November 28, 2012
Five Star Equities Provides Stock Research on Amarin and InterMune Read More
from Marketwired News Releases
Free Research Reports on AMCX, ITMN, LEAP and SVNT Issued by the Bedford Report
November 09, 2012
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
November 07, 2012
from PR Newswire
InterMune To Release Third Quarter Financial Results On November 7
October 31, 2012
from PR Newswire
FDA Considering Faster Pathway for Treatments of Deadly or Debilitating Diseases
October 19, 2012
The Paragon Report Provides Stock Research on InterMune and ACADIA Pharmaceuticals Read More
from Marketwired News Releases
Free Reports on Alcatel Lucent, InterMune, Cree and MGIC Provided by the Bedford Report
October 18, 2012
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the CAPITAL NEWS CIRCUIT. Read More
from Marketwired News Releases
Health Canada Approves Esbriet® as First Treatment for Fatal Lung Disease
October 02, 2012
- Novel oral therapy slows progression of IPF in mild to moderate patients - Read More
from PR Newswire
France's Economic Committee (CEPS) Authorizes Reimbursement of Esbriet® (pirfenidone)
September 11, 2012
-- Company to host conference call and webcast at 8 a.m. EDT -- Read More
from PR Newswire
InterMune Reports New Analyses from the RECAP Study of Esbriet® (pirfenidone) at ERS
September 03, 2012
from PR Newswire
InterMune Announces Presentations of New Research in IPF at ERS
August 27, 2012
from PR Newswire
InterMune Reports Second Quarter 2012 Financial Results and Business Highlights
July 23, 2012
- Finalizes price of Esbriet® in Germany - Read More
from PR Newswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here